CoronaVac

Overview

CoronaVac was developed by Sinovac Biotech (Beijing, China) using whole-virion inactivation — the same fundamental technology as the Salk inactivated poliovirus vaccine (1955), inactivated influenza vaccines, and hepatitis A vaccines. It presents the immune system with an entire inactivated SARS-CoV-2 virion, giving it the broadest antigen repertoire of any COVID-19 vaccine deployed at scale: spike, nucleocapsid (N), membrane (M), and envelope (E) proteins are all present and immunogenic.

Sinovac produced over 2.3 billion doses — the single largest production run of any COVID-19 vaccine globally. It was central to Brazil's early 2021 vaccination campaign (Butantan Institute manufacturing partnership), Turkey's Phase 3 trial (83.5% VE), and Chile's national programme — the subject of the landmark Jara et al. NEJM 2021 real-world effectiveness study. WHO Emergency Use Listing was granted on June 1, 2021, enabling COVAX procurement for countries without ultra-cold chain infrastructure.

CoronaVac's vaccine-efficacy estimates varied significantly across Phase 3 trials — from 50.7% in Brazil (during a Gamma [P.1] surge in healthcare workers) to 83.5% in Turkey — differences attributable to variant composition, schedule (0-and-14 vs. 0-and-28 day), and occupational exposure intensity. Chile's nationally representative real-world data provide the most robust effectiveness estimates: a steep gradient from symptomatic VE (~66%) to death VE (~86%) mirrors the pattern seen with all COVID-19 vaccines, illustrating that even moderate efficacy against symptomatic infection can translate to strong protection against severe outcomes.

Platform & Antigen Design

Whole-Virion BPL Inactivation

  SARS-CoV-2 CZ02 clinical isolate
        │
        ▼
  Vero cell propagation (high-titer batch production)
        │
        ▼
  Beta-propiolactone (BPL) inactivation
    - BPL alkylates viral RNA → abolishes replication capacity
    - Surface glycoproteins (spike, M, E) largely intact
    - Internal nucleocapsid protein (N) preserved
    - Antigen repertoire: S + N + M + E (broadest of any COVID-19 vaccine)
        │
        ▼
  Ultrafiltration + sucrose density gradient purification
        │
        ▼
  Adsorption to aluminum hydroxide (alum) adjuvant
    - Depot at injection site: slow antigen release
    - NLRP3 inflammasome activation → IL-1β, IL-18
    - Th2-skewed humoral response (IgG1/IgE in animal models)
    - Germinal center B-cell activation → anti-spike IgG
        │
        ▼
  IM injection → antigen uptake by DCs at injection site
        ├─ MHC II: viral peptides → CD4⁺ T helper priming (Th2/Tfh)
        ├─ MHC I: nucleocapsid + other internal protein peptides (cross-presentation)
        └─ Anti-spike + anti-N IgG production; seroconversion 92–100%

1. Broad antigen coverage: Whole-virion vaccine presents spike, nucleocapsid (N), M, and E — N is highly conserved across SARS-CoV-2 variants and elicits T-cell responses potentially cross-protective against emerging variants.
2. Alum depot mechanism: Aluminum hydroxide forms a slow-release depot at the injection site, extending antigen exposure for APCs and skewing the response toward Th2-mediated humoral immunity (strong IgG, weaker cellular arm).
3. NLRP3 activation: Alum activates the NLRP3 inflammasome, producing IL-1β and IL-18 — innate cytokines that augment DC maturation and provide the danger signal for adaptive priming.
4. Standard cold chain: 2–8°C — fully compatible with existing routine vaccine infrastructure worldwide, operationally decisive for deployment in Brazil, Indonesia, Turkey, and much of the developing world.
5. No novel platform risk: Inactivated vaccines have a century-long safety record; no VITT risk (no adenovirus vector), no myocarditis signal (no mRNA/LNP), no disseminated infection risk (no live organism).

Immunogenicity

Clinical Efficacy

Safety Profile

• Common Injection-site pain, erythema, induration — 30–40% of vaccinees; lower frequency than mRNA vaccines. Mild and self-limiting within 1–3 days. Dose 2 reactogenicity similar to dose 1 (unlike mRNA vaccines where dose 2 is markedly more reactive).
• Common Systemic reactions — fatigue, headache, mild fever — ~10–15%; generally milder than mRNA vaccines. No grade 3 systemic reactogenicity distinction at this frequency.
• Not observed No VITT — no adenovirus vector component. No myocarditis signal identified in large post-authorization surveillance datasets from Brazil (~100M doses) or Chile (~20M doses).
• Not observed No vaccine-enhanced disease signal — pre-pandemic SARS-CoV-1 animal model concerns for alum-adjuvanted inactivated coronavirus vaccines were not replicated in Phase 3 or real-world clinical data.
• Special populations Immunocompromised: Safe to administer (no live pathogen); reduced immunogenicity expected; additional doses recommended. Pregnancy: WHO recommends as acceptable option during pregnancy; favorable inactivated vaccine safety precedent applies.

Administration

Connections

References

• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. JAMA. 2021;326(1):35-45. doi:10.1001/jama.2020.22136
• Tanriover MD, Doganâay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-222. doi:10.1016/S0140-6736(21)01429-X
• Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385(10):875-884. doi:10.1056/NEJMoa2106715